Drug intelligence / Profile preview

AVDESP

Development stage: Preclinical
Lead developer: Avesthagen
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

AVDESP is a biosimilar recombinant erythropoietin (EPO) developed by Avestha Gengraine Technologies (Avesthagen). It functions as an erythropoietin receptor agonist, mimicking the action of the endogenous hormone to stimulate erythropoiesis (red blood cell production) in the bone marrow. The drug is specifically designed for the treatment of anaemia associated with chronic kidney disease (CKD) and chemotherapy-induced anaemia (CIA). According to company pipeline information, AVDESP is positioned as ready to enter clinical trials, following its preclinical development phase.

Brand names: AVDESP
Other names: Erythropoietin biosimilarEPO biosimilar

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on AVDESP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVDESP.

Explore the full profile